Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic's defender embolism prevention device:

This article was originally published in Clinica

Executive Summary

Medtronic has CE marked its Defender embolic protection filter for sale in Europe. The technology is now launched in Europe for use during minimally-invasive procedures in carotid arteries, such as the implantation of stents, and saphenous vein grafts. The filter has already been used in procedures conducted by interventional cardiologists and vascular surgeons in Germany and Spain, the Minneapolis, Minnesota firm said. Made of braided Nitinol, the Defender has a peel-away delivery sheath that enables physicians to manoeuvre the device easily across lesions to the desired location. When opened, the filter acts as a basket, allowing blood flow while trapping embolic debris that may become dislodged during the stenting procedure. The Defender filter is not on sale in the US.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel